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Edited by Gianni CesareniAbstract Human histamine H1 receptor (H1R) contains ﬁve
possible phosphorylation residues (Thr140, Thr142, Ser396, Ser398
and Thr478) and the substitution of all these ﬁve residues to
alanine completely impairs agonist-induced receptor downregu-
lation. In the present study, to determine which residue(s) are
responsible for receptor downregulation, we used mutant H1Rs in
which single or multiple residues were substituted with alanine.
The results suggested that two groups, i.e., residues Thr140 and
Thr142, and residues Ser396 and Ser398, independently contributed
to H1R downregulation. Thr
140 and Ser398 mainly contributed to
downregulation, and Thr142 or Ser396 had a slight inhibitory eﬀect
on Thr140- or Ser398-mediated process, respectively.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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G protein-coupled receptor1. Introduction
Histamine H1 receptor (H1R) is expressed in both central
and peripheral tissues [1], and its expression level is dynami-
cally regulated under various physiological and pathological
conditions: upregulation of H1Rs or H1R mRNA in the elec-
trical foci in the temporal cortex of epileptic patients [2] and in
the nasal mucosa of patients with allergic rhinitis [3,4],
downregulation of H1Rs in the frontal cortex of patients with
chronic schizophrenia [5] and in the frontal and temporal areas
of patients with Alzheimer’s disease [6]. The H1R level may be
regulated under these conditions by various processes as in-
dicated for other types of G protein-coupled receptors
(GPCRs), including modulation of receptor gene transcription
[7], mRNA stability [8] and receptor degradation [9], and ag-
onist-induced receptor degradation or receptor downregula-
tion seems to play an important role among these processes.* Corresponding author. Fax: +81-88-633-9513.
E-mail address: hfukui@ph.tokushima-u.ac.jp (H. Fukui).
Abbreviations: H1R, histamine H1 receptor; GPCR, G protein-coupled
receptor; CHO, Chinese hamster ovary; PKG, cGMP-dependent
protein kinase
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doi:10.1016/j.febslet.2004.07.072Stimulation of GPCR leads to intracellular signaling, but
chronic stimulation generally induces desensitization or un-
coupling of the receptor from the eﬀector system, and there-
after leads to internalization of the receptor to the intracellular
membranes. The internalized receptor may be recycled to the
cell surface, but continued stimulation of the receptor leads to
degradation or downregulation of the receptor [9–11]. Al-
though precise mechanism for such receptor downregulation
has not been clariﬁed yet, it is probable that certain amino acid
residues in the receptor can be a signal that should be de-
graded, and in fact, residues responsible for receptor down-
regulation have been identiﬁed in several GPCRs [12–16].
These residues may be involved in the process of sorting of the
internalized receptor either to the cell surface for recycling or
to lysosomes for proteolysis. Thus, in a previous study, we
explored residues of human H1R that were responsible for
agonist-induced receptor downregulation, and identiﬁed ﬁve
residues possibly involved in the process, i.e., Thr140, Thr142,
Ser396, Ser398 and Thr478 [17]. Substitution of all of these ﬁve
residues with alanine did not aﬀect histamine response or in-
ternalization of H1R, but it completely impaired agonist-in-
duced H1R downregulation. In this study, we further
delineated the residues involved in H1R downregulation by
using mutant receptors in which single or multiple residues
were substituted with alanine. The data indicate that Thr140
and Ser398 are mainly responsible for receptor downregulation,
and Thr142 and Ser396 have a modulatory role.2. Materials and methods
2.1. Materials
[3H]Mepyramine ([pyridinyl-5-3H]pyrilamine, 0.74 TBq/mmol) was
purchased from NEN Life Science Products (Boston, MA, USA). Cell
culture reagents were from Life Technologies (Rockville, MD, USA).
All other reagents, unless otherwise stated, were of analytical grade
and were from Wako Pure Chemicals (Osaka, Japan) or Sigma (St.
Louis, MO, USA).2.2. Plasmid construction
The BclI fragment (1.8 kilobase pairs) of the human H1R gene was
subcloned into the M13 mp19 phage at the EcoRI site by using EcoRI–
NotI–BamHI adaptors (Takara Biochemicals, Kyoto, Japan). Then, the
coding region of the H1R gene was subcloned into a pBluescript SK(+)
vector (Stratagene, La Jolla, CA, USA). Site-directed mutagenesis wasation of European Biochemical Societies.
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System (Amersham, Buckinghamshire, UK) and long-range polymer-
ase chain reaction system [18]. Three groups of mutant H1Rs were
constructed. First, each of the ﬁve possible phosphorylation residues,
i.e., Thr140, Thr142, Ser396, Ser398 and Thr478, was substituted with ala-
nine, forming mutant receptors designated T140A, T142A, S396A,
S398A andT478A. Second, one of the above ﬁve residues was left intact,
while the other four residues were all substituted with alanine, forming
mutant H1Rs designated 4A-140T, 4A-142T, 4A-396S, 4A-398S and
4A-478T. Third, the pair of residues Thr140 and Thr142 or Ser396 and
Ser398 was left intact, while the other three residues were replaced with
alanine (3A-140T142T and 3A-396S398S). The nucleotide sequences of
the mutated H1R genes were conﬁrmed by the dideoxynucleotide
method. Each coding region of wild-type and themutantH1R genes was
subcloned into a mammalian expression vector, pdKCR-dhfr for stable
expression in Chinese hamster ovary (CHO) cells. The constructs
contained 50 untranslated region (140 bp) and 30 untranslated region
(182 bp) of H1R gene. The 5
0 untranslated region does not contain any
potential binding sites for transcription factors.NH2
T140
T142
[2nd IL]                                 
Fig. 1. Schematic representation illustrating the sites of mutation of human
various mutants by alanine. Shown underneath are the mutant H1Rs used i
intracellular loops and the carboxyl terminus of human H1R are shown, in w
The amino acid numbers in the sequence are shown to the right of the sequenc
indicate the residues without mutation. The naming for each mutant recepto2.3. Construction of stable CHO transformants
CHO cells that were deﬁcient in dihydrofolate reductase were
transfected with the plasmid constructs using the calcium phosphate
precipitation method [19]. The cells were cultured in a-minimum es-
sential medium without ribonucleosides and deoxyribonucleosides
supplemented with 10% dialyzed fetal calf serum. Then, individual
colonies were screened for stable expression of the H1R using a
[3H]mepyramine binding assay.
2.4. Radioligand binding assay
The [3H]mepyramine binding assay was performed as described
previously [20]. A suspension of cell membranes (150–300 lg of pro-
tein) was incubated with [3H]mepyramine in the absence (total bind-
ing) or presence (non-speciﬁc binding) of 10 lM triprolidine in 50 mM
sodium–potassium phosphate buﬀer (pH 7.4) at 25 C for 60 min in a
ﬁnal volume of 600 ll. The membrane-bound radioligands were sep-
arated from free radioligands by rapid ﬁltration through a Whatman
GF/B glass ﬁber ﬁlter (Whatman, Maidstone, UK). The ﬁlter was
placed in 10 ml of Aquasol II (Packard Instrument Inc., Meriden, CT,S396S398
COOH
T478
 [3rd IL]                              [C terminus]
EXTRACELLULAR
CYTOPLASMIC
H1R. Filled circles indicate serine or threonine residues substituted in
n this study. Partial amino acid sequences of the second and the third
hich asterisked residues indicate residues that were replaced by alanine.
es. ‘‘A’’ indicates the residue that was replaced by alanine and hyphens
r is shown in Section 2.
Table 1
Binding characteristics of wild-type (WT) and mutant H1Rs expressed
in CHO cells
Receptor [3H]Mepyramine binding
Kd (nM) Bmax (pmol/mg protein)
WT 1.17 0.45 1.30 0.15
5MT 1.19 0.39 1.71 0.13
T140A 0.93 0.07 1.75 0.06
T142A 1.30 0.18 1.81 0.13
S396A 1.09 0.13 1.08 0.06
S398A 1.14 0.09 1.57 0.08
T478A 1.78 0.34 1.35 0.10
4A-140T 0.59 0.25 1.38 0.13
4A-142T 0.84 0.11 2.42 0.14
4A-396S 1.37 0.23 2.20 0.26
4A-398S 0.74 0.18 3.99 0.19
4A-478T 1.67 0.16 4.55 0.13
3A-140T142T 0.64 0.05 2.42 0.20
3A-396S398S 0.40 0.12 1.03 0.16
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tillation counter.
2.5. Receptor downregulation assay
Nearly conﬂuent cells were incubated at 37 C for 24 h in the a-
minimum essential medium described above supplemented with 10%
fetal calf serum in the presence or absence of 100 lM histamine.
Following the incubation, the cells were washed three times with ice-
cold 50 mM sodium-potassium phosphate buﬀer (pH 7.4) and were
then scraped into a small volume of the same buﬀer. The cells were
then homogenized with an ultrasonic disruptor (Tomy Seiko Co, Ltd.,
Tokyo, Japan) and centrifuged at 50 000 · g for 30 min. The pelleted
membranes were resuspended in the same buﬀer and radioligand
binding was performed as described above. Downregulation was de-
ﬁned as the decrease in speciﬁc [3H]mepyramine binding due to ex-
posure of the cells to the desensitizing agent [21]. Changes in H1R
density were expressed as a percentage of [3H]mepyramine binding of
the histamine-treated cells to that of non-treated cells. Statistical
evaluation of signiﬁcant diﬀerences was performed with Student’s t
test.Plasmamembranes were prepared from CHO cells expressing wild-type
or mutant H1Rs and [
3H]mepyramine binding assays were performed
as described in Section 2. Kd and Bmax values for [
3H]mepyramine
binding were obtained from Scatchard plots. Results represent
means S.E.M. of three independent experiments.
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3.1. Expression of mutant H1Rs in CHO cells
In a previous study, we constructed a mutant H1R (5MT
H1R), in which all of the threonines and serines of the possible
phosphorylation residues of human H1R (Thr
140, Thr142,
Ser396, Ser398 and Thr478) were substituted with alanine [17].
Properties of CHO cells expressing 5MT H1R were compara-
ble with those of cells expressing wild-type H1R (WT H1R) in
antagonist binding, agonist binding, histamine-induced inosi-
tol phosphate formation and histamine-induced receptor in-
ternalization. However, the mutant H1R was completely
resistant to histamine-induced receptor downregulation, sug-
gesting that these ﬁve residues are responsible for H1R
downregulation [17]. In the present study, to delineate the role
of each residue in H1R downregulation, we studied three
groups of mutant H1Rs that were constructed as described in
Fig. 1. First, each of the ﬁve residues was substituted with
alanine (T140A, T142A, S396A, S398A and T478A). Second,
each of the ﬁve residues was left intact while the other four
residues were all replaced with alanine (4A-140T, 4A-142T,
4A-396S, 4A-398A and 4A-478T). Third, residues of Thr140
and Thr142 or residues of Ser396 and Ser398 were left intact, and
the other three residues were replaced with alanine (3A-
140T142T and 3A-396S398S). Then, the pdKCR-dhfr vectors
containing wild-type or mutant H1R gene were transfected by
calcium phosphate precipitation method into dihydrofolate
reductase-deﬁcient CHO cells. Stable transfectants were se-
lected in the medium devoid of nucleosides and clonal cell lines
were isolated for each type of H1R. The binding characteristics
of wild-type and mutant H1Rs expressed in CHO cells are
shown in Table 1. Each cell had nearly the same binding
properties.Fig. 2. Histamine-induced downregulation of wild-type (WT) and the
mutant human H1Rs expressed in CHO cells. In the mutant H1Rs,
each of the ﬁve residues Thr140, Thr142, Ser396, Ser398 and Thr478 was
substituted with alanine, forming mutant receptors designated T140A,
T142A, T478A, S396A and S398A. Cells were treated with 100 lM
histamine at 37 C for 24 h and washed with ice-cold phosphate buﬀer.
Then, membrane preparations were prepared and were subjected to
[3H]mepyramine binding assays. The [3H]mepyramine binding for each
point is expressed as a percentage of [3H]mepyramine binding mea-
sured in non-treated cells. Each bar represent meansS.E.M. of 4–8
independent experiments. The asterisks indicate a signiﬁcant diﬀerence
compared with wild-type H1R (***P < 0:001).3.2. Histamine-induced downregulation of mutant H1Rs
expressed in CHO cells
Downregulation or degradation of H1R was assessed by
measuring an agonist-induced decrease in binding sites of li-
pophilic tracer [3H]mepyramine, which can penetrate the cell
membrane and thus label total receptors in the cell [17,22].
CHO cells expressing wild-type or mutant H1R were treated
with 100 lM histamine at 37 C for 24 h and then cells were
washed with ice-cold phosphate buﬀer. The cells were scrapedinto a small volume of the same buﬀer and membrane prepa-
rations were prepared as described in Section 2. Then, the
membrane preparations were subjected to [3H]mepyramine
binding assays.
As we showed previously [17], [3H]mepyramine binding sites
were decreased by approximately 60% upon treatment with
histamine for 24 h in cells expressing wild-type H1R, but were
scarcely not in cells expressing 5MT H1R. As the ﬁrst step to
identify the residue(s) responsible for H1R downregulation, we
studied mutant H1Rs in which one residue was substituted with
alanine. As shown in Fig. 2, H1R downregulation was signiﬁ-
cantly inhibited in cells expressing T140A or S398A H1R, but
S. Horio et al. / FEBS Letters 573 (2004) 226–230 229was not in cells expressing T142A, S396A or T478A H1R. This
result indicates that both Thr140 and Ser398 are responsible for
the downregulation process, since the mutation at either Thr140
or Ser398 aﬀected H1R downregulation. However, their con-
tribution to downregulation remained unclear, since either
mutation inhibited downregulation only partially.
Therefore, in the next step, we studied mutant H1Rs in which
one residue was left intact and the other four residues were all
replaced with alanine. As shown in Fig. 3A, both mutants, 4A-
140T and 4A-398S H1Rs, were downregulated to the same
extent as wild-type H1R was. Other mutants, 4A-142T and 4A-
396S, were downregulated signiﬁcantly compared with 5MT
H1R ðP < 0:001Þ but to a lesser extent compared with wild-type
H1R (signiﬁcantly diﬀerent). This result indicates that Thr
140
alone or Ser398 alone could fully induce H1R downregulation.
On the other hand, Thr142 or Ser396 contributed to downregu-WT  4A-  4A- 4A-   4A-  4A-    5MT
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Fig. 3. Histamine-induced downregulation of wild-type (WT) and the
mutant human H1Rs expressed in CHO cells. (A) In the mutant H1Rs,
one of the ﬁve phosphorylation residues was left intact and the other
four residues were substituted with alanine residues, forming mutant
receptors designated 4A-140T, 4A-142T, 4A-396S, 4A-398S and 4A-
478T. (B) Two of the ﬁve phosphorylation residues of H1R were left
intact and the other three residues were substituted with alanine,
forming mutant receptors, 3A-140T142T and 3A-396S398S. Cells were
treated with 100 lM histamine at 37 C for 24 h and washed with ice-
cold phosphate buﬀer. Then, membrane preparations were prepared
and were subjected to [3H]mepyramine binding assays. The [3H]me-
pyramine binding for each point is expressed as a percentage of
[3H]mepyramine binding measured in non-treated cells. Each bar
represent meansS.E.M. of 4–8 independent experiments. The as-
terisks indicate a signiﬁcant diﬀerence compared with wild-type H1R
(**P < 0:01, ***P < 0:001).lation signiﬁcantly but only partially. The 4A-478T mutant
receptor was downregulated only slightly, indicating that
Thr478 had marginal eﬀect on downregulation.
The above results suggest that there are two groups of
residues in the intracellular domain of H1R that are in-
volved in H1R downregulation; a pair consisting of Thr
140
and Thr142 in the second intracellular loop and another pair
consisting of Ser396 and Ser398 in the third intracellular loop.
Thus, to examine the role of each pair of residues, we
studied mutants in which residues Thr140 and Thr142 (3A-
140T142T) or residues Ser396 and Ser398 (3A-396S398S) were
intact and the other three residues were replaced with ala-
nine. As shown in Fig. 3B, both mutants were downregu-
lated signiﬁcantly (P < 0:001, compared with 5MT H1R),
but the extent of downregulation was signiﬁcantly less
compared with wild-type H1R. These results indicate that
Thr142 and Ser396 may have inhibitory eﬀect on Thr140- and
Ser398-mediated downregulation, respectively. Thus, each
pair of residues in the second and third intracellular loops
contributed to downregulation only partially, and they
probably took part in downregulation in an additive way for
the process to proceed in full.4. Discussion
The present study examined the role of residues Thr140,
Thr142, Ser396, Ser398 and Thr478 of human H1R in agonist-
induced receptor downregulation, and the data clearly indicate
that residues Thr140 and Ser398 are responsible for this process.
This conclusion is based on the results that mutation of either
Thr140 or Ser398 to alanine aﬀected H1R downregulation
(Fig. 2), and the results that the mutant H1R in which either
Thr140 or Ser398 was left intact and the other four residues were
replaced with alanine underwent downregulation completely
(Fig. 3A). The latter results indicate that Thr140 alone or Ser398
alone was suﬃcient for inducing full downregulation. There-
fore, there seem to be two groups of residues that participate in
H1R downregulation, i.e., Thr
140 in the second intracellular
loop and Ser398 in the third loop. Point mutations at either
Thr140 or Ser398 were not fully eﬀective in inhibiting receptor
downregulation, and this was probably because the downreg-
ulation process was mediated by the two group of residues and
the mutation introduced into one group was insuﬃcient to
inhibit downregulation completely.
Downregulation mediated by these two residues, Thr140 and
Ser398, seems to be modulated by other residues that reside
nearby, i.e., Thr142 and Ser396 may inhibit Thr140- and Ser398-
mediated processes, respectively. This was elucidated from the
results that mutant H1Rs, 3A-140T142T or 3A-396S398S un-
derwent only partial downregulation compared with full
downregulation induced by mutant H1Rs, 4A-140T or 4A-
398S (Fig. 3). Interestingly, Thr142 alone (4A-142T) or Ser396
alone (4A-396S) eﬀectively induced downregulation, although
the extent of downregulation was signiﬁcantly less compared
to that of wild-type H1R (Fig. 3A). This result may suggest
that these residues contribute in part to the downregulation
process. However, it is to be noted that this result was obtained
in the condition that both Thr140 and Ser398 were replaced with
alanine. Probably, in this condition Thr142 or Ser396 has
mimicked the action of Thr140 or Ser398 that resided nearby
and thus induced downregulation to some extent, respectively.
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did not aﬀect downregulation at all, indicating the minor role
of these residues in inducing receptor downregulation. There-
fore, although it is still speculative, it is probable that Thr142
and Ser396 have a modulatory role to inhibit Thr140- and
Ser398-mediated process, respectively. Thus, it seems that two
groups of residues participate in H1R downregulation, one
Thr140 and Thr142 in the second intracellular loop, and another
Ser396 and Ser398 in the third loop. Each pair of residues
contributes to downregulation partially, and they can induce
full downregulation in conjunction with each other.
How Thr142 and Ser398 are involved in H1R downregula-
tion? In a previous study, we showed data that the mutant
(5MT) H1R, in which all of the ﬁve residues were replaced
with alanine, was internalized properly but was completely
resistant to downregulation, suggesting that the mutant re-
ceptor was impaired in the process of receptor traﬃcking
from endosomes to lysosomes [17]. Therefore, one possible
mechanism is that the residues Thr140 and Ser398 are respon-
sible for the process of sorting the internalized receptor to
lysosomes. Recent studies have identiﬁed cytoplasmic se-
quences present in certain GPCRs that promote sorting of
internalized receptors to lysosomes [13], or those that pro-
mote or prevent recycling of receptors from endosomes to the
plasma membrane [12,14,16]. The residues identiﬁed in this
study can be a sorting signal that is responsible for receptor
traﬃcking to lysosomes, but they have no similarity with any
of the reported one.
In this study, H1R downregulation was induced by stimu-
lation with histamine. Since H1R stimulation phosphorylates
H1R [23], it is possible that agonist-induced phosphorylation
of the residues of Thr140 and Ser398 are involved in H1R
downregulation. In fact, our previous study suggested that
these two residues are substrates for several kinases [17,24].
However, there have been no convincing data indicating that
H1R phosphorylation is involved in H1R downregulation.
For example, Smit et al. [22] showed that activation of pro-
tein kinase C by phorbol esters had no eﬀect on H1R
downregulation. Miyoshi et al. [25] showed that a speciﬁc
inhibitor of cGMP-dependent protein kinase (PKG) sup-
pressed H1R downregulation, but direct activation of PKG
did not induce H1R downregulation. Consequently, at pres-
ent, whether phosphorylation of H1R, especially that of res-
idues of Thr140 and Ser398, is involved in H1R
downregulation remains to be determined. It is interesting
whether Thr140-mediated and Ser398-mediated downregulation
occur by similar mechanisms or not. Although we have no
data to clarify this point, a growing amount of data shows
that multiple mechanisms contribute to downregulation of
GPCRs [26], and thus, it is possible that downregulation
mediated by Thr142 and that by Ser398 occur through quite
diﬀerent mechanisms.Acknowledgements: This work was supported in part by Grant-in-Aid
for Scientiﬁc Research from Japan Society for the Promotion of Sci-
ence and by a fund from the Osaka Medical Research Foundation for
Incurable Diseases.References
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